Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Crohns Colitis ; 18(1): 65-74, 2024 Jan 27.
Artículo en Inglés | MEDLINE | ID: mdl-37522878

RESUMEN

BACKGROUND: Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail are limited. AIMS: To compare the durability, effectiveness, and safety of vedolizumab and ustekinumab after anti-TNF failure or intolerance in CD. METHODS: CD patients from the ENEIDA registry who received vedolizumab or ustekinumab after anti-TNF failure or intolerance were included. Durability and effectiveness were evaluated in both the short and the long term. Effectiveness was defined according to the Harvey-Bradshaw index [HBI]. The safety profile was compared between the two treatments. The propensity score was calculated by the inverse probability weighting method to balance confounder factors. RESULTS: A total of 835 patients from 30 centres were included, 207 treated with vedolizumab and 628 with ustekinumab. Dose intensification was performed in 295 patients. Vedolizumab [vs ustekinumab] was associated with a higher risk of treatment discontinuation (hazard ratio [HR] 2.55, 95% confidence interval [CI]: 2.02-3.21), adjusted by corticosteroids at baseline [HR 1.27; 95% CI: 1.00-1.62], moderate-severe activity in HBI [HR 1.79; 95% CI: 1.20-2.48], and high levels of C-reactive protein at baseline [HR 1.06; 95% CI: 1.02-1.10]. The inverse probability weighting method confirmed these results. Clinical response, remission, and corticosteroid-free clinical remission were higher with ustekinumab than with vedolizumab. Both drugs had a low risk of adverse events with no differences between them. CONCLUSION: In CD patients who have failed anti-TNF agents, ustekinumab seems to be superior to vedolizumab in terms of durability and effectiveness in clinical practice. The safety profile is good and similar for both treatments.


Asunto(s)
Anticuerpos Monoclonales Humanizados , Enfermedad de Crohn , Ustekinumab , Humanos , Ustekinumab/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Inducción de Remisión , Factor de Necrosis Tumoral alfa , Sistema de Registros , Resultado del Tratamiento , Estudios Retrospectivos
2.
Enferm. clín. (Ed. impr.) ; 24(2): 102-110, mar.-abr. 2014. ilus, tab
Artículo en Español | IBECS | ID: ibc-120818

RESUMEN

INTRODUCCIÓN: El manejo de los pacientes con enfermedad inflamatoria intestinal (EII) se asocia a un importante consumo de recursos sanitarios. En el año 2009 se creó en el CHUVI una consulta de enfermería en patología digestiva, con disponibilidad de atención telemática. El notable incremento en esta área nos estimula a cuantificar el ahorro de lo que esta atención puede suponer para el sistema de salud. OBJETIVOS: 1) Valorar los resultados de la puesta en marcha de una consulta telemática. 2) Valorar la capacidad de resolución telemática por parte de enfermería. 3) Estimar el posible ahorro de la consulta telemática de EII. MATERIAL Y MÉTODO: Recogida de la actividad telemática de 2009 a 2011. Análisis estimado del ahorro sanitario, mediante la aplicación de las tarifas por servicios sanitarios del SERGAS, para demandas originadas por aparición de nueva clínica/brote de actividad de EII. Análisis de datos con SPSS 15.0. RESULTADOS: Existe un aumento lineal significativo de la resolución telefónica de demandas por parte de enfermería (p = 0,03) y una reducción de las que precisan acudir a consulta médica (p < 0,0001). De las demandas por brote (n = 452), solo han requerido atención en el servicio de urgencias 65 (14,38%), precisando su ingreso 33 (7,3%). El cálculo del ahorro medio estimado en 2009-2011 ascendería de media a 73.603 €. CONCLUSIONES: Se objetiva un aumento de la capacidad de resolución de la atención telemática por parte de enfermería. En cuanto al ahorro estimado, podemos concluir que la atención telemática consigue un ahorro significativo de los costes sanitarios, que justifica la implementación de una consulta de enfermería en patología digestiva


INTRODUCTION: The management of patients with inflammatory bowel disease (IBD) is associated with a significant use of healthcare resources. In 2009, a digestive diseases nursing consultation, with availability of health telematic media was created in our hospital (CHUVI). The important activity performed in this area encouraged us to quantify the cost savings for the care health system. AIMS: 1) To evaluate the results of the implementation of a telematic IBD consultation. 2) To assess the capacity for resolving problems by nurses. 3) To estimate the potential cost savings of telematic nursing consultation in IBD. MATERIAL AND METHOD: We collected data on telematic activity from 2009 to 2011. The estimated cost saving was calculated by applying the fees for health services published by our National Health Service (SERGAS) for care in new outbreaks of IBD activity. Data were analyzed with SPSS 15.0. RESULTS: There was a significant linear increase on the resolution of telephone demands by nurses (P = .03) and an important decrease of demands needing medical advice (P < .0001). Focusing on IBD outbreak claims (n = 452), only 65 patients (14.38%) required medical attention in emergency services, and 33 (7.3%) were hospitalized. Altogether we calculated an average cost saving since 2009 to 2011 of 73,603 €. CONCLUSIONS: We found a gradual increase in resolving telematic care demands by nurses. Telematic consultation can lead to significant cost savings, which justify the implementation of a digestive diseases nurse consultation


Asunto(s)
Humanos , Enfermedades Inflamatorias del Intestino/enfermería , Consulta Remota/métodos , Telemedicina/tendencias , Enfermedad de Crohn/enfermería , Colitis Ulcerosa/enfermería
3.
Enferm Clin ; 24(2): 102-10, 2014.
Artículo en Español | MEDLINE | ID: mdl-24440551

RESUMEN

INTRODUCTION: The management of patients with inflammatory bowel disease (IBD) is associated with a significant use of healthcare resources. In 2009, a digestive diseases nursing consultation, with availability of health telematic media was created in our hospital (CHUVI). The important activity performed in this area encouraged us to quantify the cost savings for the care health system. AIMS: 1) To evaluate the results of the implementation of a telematic IBD consultation. 2) To assess the capacity for resolving problems by nurses. 3) To estimate the potential cost savings of telematic nursing consultation in IBD. MATERIAL AND METHOD: We collected data on telematic activity from 2009 to 2011. The estimated cost saving was calculated by applying the fees for health services published by our National Health Service (SERGAS) for care in new outbreaks of IBD activity. Data were analyzed with SPSS 15.0 RESULTS: There was a significant linear increase on the resolution of telephone demands by nurses (P=.03) and an important decrease of demands needing medical advice (P<.0001). Focusing on IBD outbreak claims (n=452), only 65 patients (14.38%) required medical attention in emergency services, and 33 (7.3%) were hospitalized. Altogether we calculated an average cost saving since 2009 to 2011 of 73,603€. CONCLUSIONS: We found a gradual increase in resolving telematic care demands by nurses. Telematic consultation can lead to significant cost savings, which justify the implementation of a digestive diseases nurse consultation.


Asunto(s)
Enfermedades Inflamatorias del Intestino/economía , Enfermedades Inflamatorias del Intestino/enfermería , Consulta Remota/economía , Consulta Remota/normas , Costos y Análisis de Costo , Estudios Transversales , Femenino , Humanos , Masculino , Personal de Enfermería
5.
Gastroenterol Hepatol ; 35(8): 602-7, 2012 Oct.
Artículo en Español | MEDLINE | ID: mdl-22749509
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...